Biological mechanism of antidepressant effect of omega-3 fatty acids: How does fish oil act as a 'mind-body interface'?

NeuroSignals

Volumn 17, Issue 2, 2009, Pages 144-152

  Su, Kuan Pin ^a,b,c  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Arachidonic acid; Cyclo oxygenase 2; Depression; Docosahexaenoic acid; Eicosapentaenoic acid; Leukotrienes; Major depressive disorder; Phospholipase A2; Prostaglandins; Thromboxanes

Indexed keywords

ALPHA INTERFERON; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CYCLOOXYGENASE 2; CYTOKINE; DOCOSAHEXAENOIC ACID; FISH OIL; ICOSAPENTAENOIC ACID; INTERLEUKIN 2; LITHIUM; MOOD STABILIZER; OMEGA 3 FATTY ACID; PROSTAGLANDIN E2; VALPROIC ACID;

ABDOMINAL PAIN; ANOREXIA; ANXIETY; ARTHRALGIA; ASTHENIA; BIPOLAR DEPRESSION; CELL FUNCTION; CHRONIC DISEASE; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DIET; FATIGUE; FATTY ACID SYNTHESIS; FISH; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS C; HUMAN; ILLNESS BEHAVIOR; IMMUNITY; INSOMNIA; MAJOR DEPRESSION; MENTAL CONCENTRATION; MOOD DISORDER; MUSCULOSKELETAL PAIN; NEOPLASM; NERVE CELL MEMBRANE; NERVE CONDUCTION; NEUROIMMUNOLOGY; NONHUMAN; PSYCHOMOTOR DISORDER; REVIEW; SIDE EFFECT;

AFFECT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DIET; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; HUMANS; MODELS, BIOLOGICAL; NEURONS; PSYCHONEUROIMMUNOLOGY; PSYCHOPHYSIOLOGY;

EID: 59149104081     PISSN: 1424862X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000198167     Document Type: Review

References (104)

1. The World Health Report: Mental Health: New Understanding, New Hope. Geneva, WHO, 2001.
2. Berton O, Nestler EJ: New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006; 7: 137-151.
3. Simon GE, VonKorff M, Piccinelli M, Fullerton C, Ormel J: An international study of the relation between somatic symptoms and depression. N Engl J Med 1999; 341: 1329-1335.
4. Katon W, Sullivan MD: Depression and chronic medical illness. J Clin Psychiatry 1990; 51(suppl):3-11.
5. Skolnick P: Beyond monoamine-based therapies: clues to new approaches. J Clin Psychiatry 2002; 63(suppl 2):19-23.
6. Horrobin DF, Bennett CN: Depression and bipolar disorder: relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, ageing and osteoporosis. Possible candidate genes. Pros-taglandins Leukot Essent Fatty Acids 1999; 60: 217-234.
7. Horrobin DF: Phospholipid metabolism and depression: the possible roles of phospholipase A2 and coenzyme A-independent transacylase. Hum Psychopharmacol 2001; 16: 45-52.
8. Su KP, Shen WW, Huang SY: Effects of polyunsaturated fatty acids on psychiatric disorders. Am J Clin Nutr 2000; 72: 1241.
9. Das UN: Essential fatty acids: biochemistry, physiology and pathology. Biotechnol J 2006; 1: 420-439.
10. Torpy JM, Lynm C, Glass RM: JAMA patient page. Eating fish: health benefits and risks. JAMA 2006; 296: 1926.
11. Connor WE: Importance of n-3 fatty acids in health and disease. Am J Clin Nutr 2000; 71: 171S-175S.
12. Chalon S: Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins Leukot Essent Fatty Acids 2006; 75: 259-269.
13. Su KP, Huang SY, Chiu CC, Shen WW: Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 2003; 13: 267-271.
14. Farooqui AA, Ong WY, Horrocks LA: Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Pharmacol Rev 2006; 58: 591-620.
15. Hibbeln JR, Nieminen LR, Blasbalg TL, Riggs JA, Lands WE: Healthy intakes of n-3 and n-6 fatty acids: estimations considering worldwide diversity. Am J Clin Nutr 2006; 83: 1483S -1493S.
16. Hibbeln JR: Fish consumption and major depression. Lancet 1998; 351: 1213.
17. Peet M, Murphy B, Shay J, Horrobin D: Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry 1998; 43: 315-319.
18. Adams PB, Lawson S, Sanigorski A, Sinclair AJ: Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids 1996; 31(suppl):S157-S161.
19. Edwards R, Peet M, Shay J, Horrobin D: Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affect Disord 1998; 48: 149-155.
20. Maes M, Smith R, Christophe A, Cosyns P, Desnyder R, Meltzer H: Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20: 4 omega 6/C20: 5 omega 3 ratio in cholesteryl esters and phospholipids. J Affect Disord 1996; 38: 35-46.
21. Maes M, Christophe A, Delanghe J, Altamura C, Neels H, Meltzer HY: Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res 1999; 85: 275-291.
22. Freeman MP, Hibbeln JR, Wisner KL, Davis JM, Mischoulon D, Peet M, Keck PE Jr, Marangell LB, Richardson AJ, Lake J, Stoll AL: Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry 2006; 67: 1954-1967.
23. Lin PY, Su KP: A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry 2007; 68: 1056-1061.
24. Nemets B, Stahl Z, Belmaker RH: Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 2002; 159: 477-479.
25. Peet M, Horrobin DF: A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002; 59: 913-919.
26. Frangou S, Lewis M, McCrone P: Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry 2006; 188: 46-50.
27. Nemets H, Nemets B, Apter A, Bracha Z , Belmaker RH: Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am J Psychiatry 2006; 163: 1098-1100.
28. Appleton KM, Hayward RC, Gunnell D, Peters TJ, Rogers PJ, Kessler D, Ness AR: Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials. Am J Clin Nutr 2006; 84: 1308-1316.
29. Rogers PJ, Appleton KM, Kessler D, Peters TJ, Gunnell D, Hayward RC, Heatherley SV, Christian LM, McNaughton SA, Ness AR: No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial. Br J Nutr 2008; 99: 421-431.
30. Richardson AJ: n-3 Fatty acids and mood: the devil is in the detail. Br J Nutr 2008; 99: 221-223.
31. Osher Y, Bersudsky Y, Belmaker RH: Ome-ga-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study. J Clin Psychiatry 2005; 66: 726-729.
32. Su KP, Huang SY, Chiu TH, Huang KC, Huang CL, Chang HC, Pariante CM: Ome-ga-3 fatty acids for major depressive disorder during pregnancy. Results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008; 69: 644-651.
33. Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, Cress KK, Ma-rangell LB: Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999; 56: 407-412.
34. Su KP, Shen WW, Huang SY: Are omega-3 fatty acids beneficial in depression but not mania? Arch Gen Psychiatry 2000; 57: 716-717.
35. Chiu CC, Huang SY, Chen CC, Su KP: Ome-ga-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder. J Clin Psychiatry 2005; 66: 1613-1614.
36. Keck PE Jr, Mintz J, McElroy SL, Freeman MP, Suppes T, Frye MA, Altshuler LL, Kupka R, Nolen WA, Leverich GS, Denicoff KD, Grunze H, Duan N, Post RM: Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry 2006; 60: 1020-1022.
37. Freeman MP, Hibbeln JR, Wisner KL, Watchman M, Gelenberg AJ: An open trial of Omega-3 fatty acids for depression in pregnancy. Acta Neuropsychiatr 2006; 18: 21-24.
38. Hamilton M: Frequency of symptoms in melancholia (depressive illness). Br J Psychiatry 1989; 154: 201-206.
39. Tylee A, Gastpar M, Lepine JP, Mendlewicz J: DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability and current management of depression in the community. DEPRES Steering Committee. Int Clin Psychopharmacol 1999; 14: 139-151.
40. Kirmayer LJ, Robbins JM, Dworkind M, Yaffe MJ: Somatization and the recognition of depression and anxiety in primary care. Am J Psychiatry 1993; 150: 734-741.
41. Bair MJ, Robinson RL, Katon W, Kroenke K: Depression and pain comorbidity: a literature review. Arch Intern Med 2003; 163: 2433-2445.
42. Kent S, Bluthe RM, Kelley KW, Dantzer R: Sickness behavior as a new target for drug development. Trends Pharmacol Sci 1992; 13: 24-28.
43. Konsman JP, Parnet P, Dantzer R: Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci 2002; 25: 154-159.
44. Hart BL: Biological basis of the behavior of sick animals. Neurosci Biobehav Rev 1988; 12: 123-137.
45. Capuron L, Miller AH: Cytokines and psy-chopathology: lessons from interferon-al-pha. Biol Psychiatry 2004; 56: 819-824.
46. Dieperink E, Willenbring M, Ho SB: Neuro-psychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000; 157: 867-876.
47. Trask PC, Esper P, Riba M, Redman B: Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol 2000; 18: 2316-2326.
48. Raison CL, Demetrashvili M, Capuron L, Miller AH: Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005; 19: 105-123.
49. Dantzer R: Somatization: a psychoneuroim-mune perspective. Psychoneuroendocrinol-ogy 2005; 30: 947-952.
50. Milton AS: Thermoregulatory actions of eicosanoids in the central nervous system with particular regard to the pathogenesis of fever. Ann N Y Acad Sci 1989; 559: 392-410.
51. Mahony SM, Tisdale MJ: Role of prostaglandins in tumour necrosis factor induced weight loss. Br J Cancer 1989; 60: 51-55.
52. Uehara A, Ishikawa Y, Okumura T, Okamura K, Sekiya C, Takasugi Y, Namiki M: Indomethacin blocks the anorexic action of in terleukin-1. Eur J Pharmacol 1989; 170: 257-260.
53. Lands WE: Biochemistry and physiology of n-3 fatty acids. FASEB J 1992; 6: 2530-2536.
54. Song C, Li X, Leonard BE, Horrobin DF: Effects of dietary n-3 or n-6 fatty acids on in-terleukin-1beta-induced anxiety, stress, and inflammatory responses in rats. J Lipid Res 2003; 44: 1984-1991.
55. James MJ, Gibson RA, Cleland LG: Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 2000; 71: 343S-348S.
56. Song C, Phillips AG, Leonard BE, Horrobin DF: Ethyl-eicosapentaenoic acid ingestion prevents corticosterone-mediated memory impairment induced by central administration of interleukin-1beta in rats. Mol Psychiatry 2004; 9: 630-638.
57. Song C, Leonard BE, Horrobin DF: Dietary ethyl-eicosapentaenoic acid but not soybean oil reverses central interleukin-1-induced changes in behavior, corticosterone and immune response in rats. Stress 2004; 7: 43-54.
58. Kempf K, Rose B, Herder C, Kleophas U, Martin S, Kolb H: Inflammation in metabolic syndrome and type 2 diabetes: Impact of dietary glucose. Ann N Y Acad Sci 2006; 1084: 30-48.
59. Daryani A, Basu S, Becker W, Larsson A, Riserus U: Antioxidant intake, oxidative stress and inflammation among immigrant women from the Middle East living in Sweden: associations with cardiovascular risk factors. Nutr Metab Cardiovasc Dis 2006.
60. Petersen AM, Pedersen BK: The role of IL-6 in mediating the anti-inflammatory effects of exercise. J Physiol Pharmacol 2006; 57 (suppl 10):43-51.
61. Zuliani G, Ranzini M, Guerra G, Rossi L, Munari MR, Zurlo A, Volpato S, Atti AR, Ble A, Fellin R: Plasma cytokines profile in older subjects with late onset Alzheimer's disease or vascular dementia. J Psychiatr Res 2007; 41: 686-693.
62. Katon WJ: Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry 2003; 54: 216-226.
63. Delion S, Chalon S, Herault J, Guilloteau D, Besnard JC, Durand G: Chronic dietary alpha-linolenic acid deficiency alters dopaminergic and serotonergic neurotransmission in rats. J Nutr 1994; 124: 2466-2475.
64. Chalon S, Va ncassel S, Zimmer L, Guilloteau D, Durand G: Polyunsaturated fatty acids and cerebral function: focus on monoaminergic neurotransmission. Lipids 2001; 36: 937-944.
65. Berg KA, Maayani S, Clarke WP: 5-hydroxy-tryptamine2C receptor activation inhibits 5-hydroxytryptamine1B-like receptor function via arachidonic acid metabolism. Mol Pharmacol 1996; 50: 1017-1023.
66. Farooqui AA, Hirashima Y, Horrocks LA: Brain phospholipases and their role in signal transduction. Adv Exp Med Biol 1992; 318: 11-25.
67. Chalon S, Delion-Vancassel S, Belzung C, Guilloteau D, Leguisquet AM, Besnard JC, Durand G: Dietary fish oil affects monoaminergic neurotransmission and behavior in rats. J Nutr 1998; 128: 2512-2519.
68. Delion S, Chalon S, Guilloteau D, Besnard JC, Durand G: alpha-Linolenic acid dietary deficiency alters age-related changes of do-paminergic and serotoninergic neurotrans-mission in the rat frontal cortex. J Neurochem 1996; 66: 1582-1591.
69. Maes M, Meltzer HY: The serotonin hypothesis of major depression; in Bloom FE, Kupfer DJ (eds): Psychopharmacology, the Fourth Generation of Progress. New York, Raven Press, 1995, pp 933-941.
70. Hibbeln JR, Linnoila M, Umhau JC, Rawlings R, George DT, Salem N Jr: Essential fatty acids predict metabolites of serotonin and dopamine in cerebrospinal fluid among healthy control subjects, and early- and late-onset alcoholics. Biol Psychiatry 1998; 44: 235-242.
71. Nizzo MC, Tegos S, Gallamini A, Toffano G, Polleri A, Massarotti M: Brain cortex phos-pholipids liposomes effects on CSF HVA, 5-HIAA and on prolactin and somatotropin secretion in man. J Neural Transm 1978; 43: 93-102.
72. Chiu CC, Huang SY, Su KP, Lu ML, Huang MC, Chen CC, Shen WW: Polyunsaturated fatty acid deficit in patients with bipolar mania. Eur Neuropsychopharmacol 2003; 13: 99-103.
73. Linnoila M, Whorton AR, Rubinow DR, Cowdry RW, Ninan PT, Waters RN: CSF prostaglandin levels in depressed and schizophrenic patients. Arch Gen Psychiatry 1983; 40: 405-406.
74. Ohishi K, Ueno R , Nishino S, Sakai T, Hayaishi O: Increased level of salivary prostaglandins in patients with major depression. Biol Psychiatry 1988; 23: 326-334.
75. Noponen M, Sanfilipo M, Samanich K, Ryer H, Ko G, Angrist B, Wolkin A, Duncan E, Rotrosen J: Elevated PLA2 activity in schizophrenics and other psychiatric patients. Biol Psychiatry 1993; 34: 641-649.
76. Chang MC, Contreras MA, Rosenberger TA, Rintala JJ, Bell JM, Rapoport SI: Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers. J Neurochem 2001; 77: 796-803.
77. Ghelardoni S, Tomita YA, Bell JM, Rapoport SI, Bosetti F: Chronic carbamazepine selectively downregulates cytosolic phospholipase A2 expression and cyclooxygenase activity in rat brain. Biol Psychiatry 2004; 56: 248-254.
78. Das UN: Perinatal supplementation of long-chain polyunsaturated fatty acids, immune response and adult diseases. Med Sci Monit 2004; 10:HY19-HY25.
79. Farooqui AA, Ong WY, Horrocks LA: Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Pharmacol Rev 2006; 58: 591-620.
80. Rapoport SI, Bosetti F: Do lithium and anti-convulsants target the brain arachidonic acid cascade in bipolar disorder? Arch Gen Psychiatry 2002; 59: 592-596.
81. Rao JS, Lee HJ, Rapoport SI, Bazinet RP: Mode of action of mood stabilizers: is the arachidonic acid cascade a common target? Mol Psychiatry 2008; 13: 585-596.
82. Das UN: Do polyunsaturated fatty acids behave like an endogenous 'polypill'? Med Hypotheses 2008; 70:430-434.
83. Bazan NG: Cell survival matters: docosa-hexaenoic acid signaling, neuroprotection and photoreceptors. Trends Neurosci 2006; 29: 263-271.
84. Lucas KK, Svensson CI, Hua XY, Yaksh TL, Dennis EA: Spinal phospholipase A2 in inflammatory hyperalgesia: role of group I VA cPLA2. Br J Pharmacol 2005; 144: 940-952.
85. Uozumi N, Shimizu T: Roles for cytosolic phospholipase A2alpha as revealed by gene-targeted mice. Prostaglandins Other Lipid Mediat 2002; 68-69: 59-69.
86. Pae CU, Yu HS, Kim JJ, Lee CU, Lee SJ, Lee KU, Jun TY, Paik IH, Serretti A, Lee C: BanI polymorphism of the cytosolic phospholi-pase A2 gene and mood disorders in the Korean population. Neuropsychobiology 2004; 49: 185-188.
87. Su K P, Peng CY, Cheng JC, Pariante CM: Polymorphisms in cytosolic phospholipase A2 and cyclooxygenase 2 genes and risk of interferon-induced depression. Eur Neuro-psychopharmacol 2007; 17:S334-S335.
88. Su KP: Mind-body interface: the role of n-3 fatty acids in psychoneuroimmunology, somatic presentation, and medical illness co-morbidity of depression. Asia Pac J Clin Nutr 2008; 17: 147-153.
89. Pascual RM, Carr EM, Seeds MC, Guo M, Panettieri RA Jr, Peters SP, Penn RB: Regulatory features of interleukin-1beta-mediated prostaglandin E2 sy nthesis in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2006; 290:L501-L508.
90. Morioka N, Takeda K, Kumagai K, Hanada T, Ikoma K, Hide I, Inoue A, Nakata Y: Interleukin-1beta-induced substance P release from rat cultured primary afferent neurons driven by two phospholipase A2 enzymes: secretory type IIA and cytosolic type IV. J Neurochem 2002; 80: 989-997.
91. 1 Hoozemans JJ, Veerhuis R, Janssen I, Rozemuller AJ, Eikelenboom P: Interleukin-1beta induced cyclooxygenase 2 expression and prostaglandin E2 secretion by human neuroblastoma cells: implications for Alzheimer's disease. Exp Gerontol 2001; 36: 559-570.
92. Schmidlin F, Loeffler S, Bertrand C, Landry Y, Gies JP: PLA2 phosphorylation and cyclo-oxygenase-2 induction, through p38 MAP kinase pathway, is involved in the IL-1beta-induced bradykinin B2 receptor gene transcription. Naunyn Schmiedebergs Arch Pharmacol 2000; 361: 247-254.
93. Hannigan GE, Williams BR: Signal transduction by interferon-alpha through arachidonic acid metabolism. Science 1991; 251: 204-207.
94. Wu T, Levine SJ, Lawrence MG, Logun C, Angus CW, Shelhamer JH: Interferon-gam-ma induces the synthesis and activation of cytosolic phospholipase A2. J Clin Invest 1994; 93: 571-577.
95. Wolbink GJ, Schalkwijk C, Baars JW, Wag-staff J, van den BH, Hack CE: Therapy with interleukin-2 induces the systemic release of phospholipase-A2. Cancer Immunol Immunother 1995; 41: 287-292.
96. Visnjic D, Batinic D, Banfic H: Arachidonic acid mediates interferon-gamma-induced sphingomyelin hydrolysis and monocytic marker expression in HL-60 cell line. Blood 1997; 89: 81-91.
97. Ka mbe T, Murakami M, Kudo I: Poly unsaturated fatty acids potentiate interleukin-1-stimulated arachidonic acid release by cells overexpressing type IIA secretory phospho-lipase A2. FEBS Lett 1999; 453: 81-84.
98. Song C, Li X, Kang Z, Kadotomi Y: Omega-3 fatty acid ethyl- eicosapentaenoate attenuates IL-1beta-induced changes in dopamine and metabolites in the shell of the nucleus accumbens involved with PLA2 activity and corticosterone secretion. Neuropsychophar-macology 2007; 32: 736-744.
99. Tylee A, Gastpar M, Lepine JP, Mendlewicz J: DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability and current management of depression in the community. DEPRES Steering Committee. Int Clin Psychopharmacol 1999; 14: 139-151.
100. Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, Miller AH: Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychophar-macology 2002; 26: 643-652.
101. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-1492.
102. Bair MJ, Robinson RL, Eckert GJ, Stang PE, Croghan T W, Kroenke K: Impact of pain on depression treatment response in primary care. Psychosom Med 2004; 66: 17-22.
103. Yates WR, Mitchell J, John RA, Trivedi M, Wisniewski SR, Warden D, Bryan C, Fava M, Husain MM, Gaynes BN: Clinical features of depression in outpatients with and without co-occurring general medical conditions in STAR*D: confirmatory analysis. Prim Care Companion J Clin Psychiatry 2007; 9: 7-15.
104. Corruble E, Guelfi JD: Pain complaints in depressed inpatients. Psychopathology 2000; 33: 307-309.